NasdaqCM:SGMOBiotechs
Sangamo Therapeutics (SGMO) Q4 Loss Highlights Deep TTM Deficit Challenging Bullish Profitability Hopes
Sangamo Therapeutics (SGMO) closed out FY 2025 with Q4 revenue of US$14.2 million and a basic EPS loss of US$0.11, as net income excluding extra items came in at a loss of US$37.4 million. On a trailing twelve month basis, revenue was US$39.6 million with a basic EPS loss of US$0.44 and a net loss of US$122.9 million. The company has seen quarterly revenue range from US$0.6 million to US$49.4 million across the last six reported periods, with basic EPS moving between a loss of US$0.14 and a...